arrow
A

Ari M. Vanderwalde

caris life sciences
H指数:30
被引数:8,128

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression

鼻咽癌(NPC)中分子和免疫景观因生长抑素受体2(<i>SSTR2</i>)表达而异

2026-09-300
OAAI
Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC

靶向NHEJ通过MYC降解激活STING信号通路以增强SCLC的抗肿瘤免疫

2026-02-100
OAAI
Real-World Impact of Metformin on Outcomes in Patients with Deficient DNA Mismatch Repair and Microsatellite Instability (dMMR/MSI) Colorectal Cancer Treated with Immune Checkpoint Inhibitors

二甲双胍对接受免疫检查点抑制剂治疗的患者中DNA错配修复缺陷和微卫星不稳定性(dMMR/MSI)结直肠癌结局的实时世界影响

2025-12-100
OA
Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma

EZH2表达和活性的基因组与免疫相关性在嗅神经母细胞瘤中的研究

2025-11-010
OAAI
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

肺大细胞神经内分泌癌的整合分子与临床特征分析

2025-08-190
OA
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)

非小细胞肺癌(NSCLC)中获得性EGFR耐药突变的发生率及其分子相关性

2025-04-170
PRE
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
2024-04-023
OAAI
Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma
2024-03-220
PRE
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases
2023-11-146
OAAI
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
2023-08-1743
OA
CD8 T cell-melanoma cell interactions in response and resistance to ipilimumab plus nivolumab: Biopsy analysis of SWOG S1616
2023-04-040
PRE